Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.

Goal 2: Reduce Human Disease

Pulmonary Vascular Diseases

Does "goal-targeted" therapy (with adjustments/additional therapy, if certain "goals" are not achieved) improve quality of life, functional status, and survival in patients with pulmonary arterial hypertension? Trials of therapies for hepatopulmonary syndrome.

Submitted by (@nhlbiforumadministrator)

Voting

2 net votes
2 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Funding for Hemostasis & Thrombosis Research

Thrombotic disorders, a result of the inappropriate activation of the hemostatic system, remain major causes of morbidity and mortality in the United States. Cancer, cardiovascular disease, trauma, and many of the other causes of death in the U.S. frequently culminate in a fatal thrombotic event. Notably, thromboembolic disease affects 500,000 people annually and leads to 100,000 deaths in the United States alone. Current ...more »

Submitted by (@abrams)

Voting

128 net votes
136 up votes
8 down votes
Active

Goal 2: Reduce Human Disease

Biorepository to facilitate epidemiologic studies of transfusion-transmitted diseases and validation of laboratory tests for don

There is a critical need for a proactive and coordinated effort to develop well-characterized biorepositories that can be used for epidemiologic studies of emerging infectious agents to expedite rapid implementation of donor screening tests for emerging pathogens and variants that pose a threat to the blood supply.

Submitted by (@chintamani.atreya)

Voting

3 net votes
12 up votes
9 down votes
Active

Goal 2: Reduce Human Disease

Improving Representation of the Elderly in Clinical Research

There is a need to optimize long-term cognitive and functional outcomes in the aging population during and after cardiothorasic surgery, including the development of simple, objective tools to enable risk stratification for vulnerability to neurocognitive deficit. First, cardiothoracic surgical trials and clinical studies should be more "age-representative" and reflect the increasing proportion of the aging population. ...more »

Submitted by (@nhlbiforumadministrator1)

Voting

24 net votes
37 up votes
13 down votes
Active